Table 1.

Clinical data for 44 patients with heart failure treated with combination of spironolactone plus ACE inhibitors or AT₁ receptor blockers

Patient No	Age (years)	Type 2 diabetes	NYHA class	Spironolactone (mg/d)	ACE inhibitor or AT1 receptor blocker (mg/d)	Potassium (mmol/l)*	Serum creatinine (μmol/l)*	Creatinine clearance (ml/s)*†	Initial treatment	Potassium (mmol/l)‡	Creatinine (μmol/l)‡	Creatinine clearance (ml/s)‡	Outcome
1	87	Yes	III	100	Enalapril (10)	7.09	165	0.42	C	3.40	122	0.57
2	88	No	III	50	Captopril (37.5)	8.50	227	0.27	C	5.00	79	0.77
3	86	Yes	IV	100	Losartan (50)	8.50	161	0.55	HD	4.80			Long term HD
4	88	Yes	IV	200	Ramipril (1.25)	8.27	363	0.22	HD	4.50			Long term HD
5	69	Yes	III	100	Ramipril (5)	7.80	201	0.50	HD	4.80	165	0.62
6	74	Yes	III	100	Benazepril (20)	9.10	138	0.63	HD	3.60	133	0.65
8	79	Yes	III	100	Benazepril (5)	7.20	171	0.60	HD	5.40	152	0.67
8	66	Yes	IV	100	Enalapril (5)	6.40	394	0.22	HD	4.50			Long term HD
9	67	No	IV	50	Enalapril (5)	8.04	447	0.25	HD	3.94			Long term HD
10	66	Yes	III	50	Losartan (50)	7.96	108	1.12	HD	3.73	80	1.50
11	66	Yes	III	50	Losartan (50)	6.20	215	0.50	HD	4.02	133	0.80
12	69	No	III	50	Captopril (50)	8.00	750	0.13	HD	4.75	125	0.78
13	73	Yes	III	50	Losartan (50)	7.50	126	0.60	HD	5.13	98	0.78
14	56	No	IV	50	Captopril (50)	7.50	180	0.73	HD	4.20	145	0.90
15	90	Yes	III	50	Enalapril (10)	6.30	109	0.50	C	4.49	120	0.45
16	50	Yes	IV	50	Enalapril (10)	7.50	594	0.27	HD	3.80	153	1.02
17	78	Yes	III	50	Benazepril (5)	7.40	126	0.65	HD	5.20	88	0.92
18	77	Yes	III	50	Moexipril (10)	8.40	185	0.42	HD	4.35	195	0.40
19	64	Yes	III	150	Enalapril (10)	6.73	231	0.37	HD	4.22	103	0.83
20	88	Yes	III	50	Captopril (50)	6.80	192	0.35	HD	4.47			Death
21	83	No	II	100	Captopril (50)	7.36	462	0.18	HD	4.49	121	0.72
22	75	Yes	II	100	Enalapril (5)	7.60	478	0.23	HD	4.30			Death
23	51	Yes	III	50	Enalapril (5)	7.32	295	0.59	HD	4.60			Long term HD
24	89	Yes	III	100	Captopril (12.5)	6.04	304	0.18	C	4.50	220	0.27
25	76	Yes	III	100	Captopril (150), telmisartan (80)	8.66	358	0.23	HD	3.73	92	0.90
26	81	Yes	III	200	Ramipril (5)	6.67	88	1.00	HD	4.84	109	0.80
27	76	Yes	II	50	Enalapril (10)	7.40	548	0.17	HD	3.51	242	0.38
28	67	No	III	25	Enalapril (20)	8.05	517	0.20	HD	4.03	234	0.45
29	68	Yes	III	100	Enalapril (10)	8.19	288	0.43	HD	4.83	106	1.18
30	70	Yes	III	50	Benazepril (20)	6.20	165	0.68	C	3.71	119	0.95
31	85	Yes	III	150	Captopril (50)	6.50	242	0.27	C	4.18	117	0.55
32	76	Yes	III	100	Captopril (50)	7.20	231	0.35	HD	4.22	105	0.78
33	88	Yes	III	50	Enalapril (10)	7.80	288	0.22	HD	3.89	155	0.40
34	91	Yes	III	100	Captopril (50)	7.10	380	0.20	HD	4.65	180	0.42
35	69	No	II	100	Captopril (50)	7.60	340	0.28	HD	4.44	103	0.92
36	73	Yes	III	50	Enalapril (10)	6.80	195	0.59	HD	4.50	110	1.05
37	81	No	IV	50	Enalapril (10)	7.80	266	0.32	HD	4.29	241	0.35
38	73	Yes	III	100	Captopril (75)	9.36	144	0.50	HD	4.56	97	0.75
39	63	Yes	II	150	Candesartan (16)	9.65	940	0.13	HD	4.64	306	0.42
40	90	Yes	III	150	Enalapril (5)	7.19	156	0.32	C	4.99	89	0.57
41	90	Yes	III	100	Enalapril (5)	8.74	299	0.17	HD	5.30	131	0.38
42	73	Yes	III	100	Enalapril (400	8.94	288	0.25	HD	3.45			Long term HD
43	83	Yes	III	50	Enalapril (10)	8.97	246	0.27	HD	3.74	168	0.38
44	76	No	III	200	Captopril (150)	8.75	319	0.27	HD	4.73	246	0.33

NYHA=New York Heart Association; HD-haemodialysis; C=conventional potassium lowering treatment (see text).

^*On admission.

^†Calculated by the Cockroft and Gault formula (for SI units).

^‡At last follow up.